Now, a tracker that tells you about progress of Covid-19 vaccine, treatment

Even as the world continues to wait for an effective vaccine to forestall the spread of Covid-19, CSM Tech's 'CoVaTrack' will serve as the first India-focused Covid-19 vaccine and treatment tracker

Coronavirus
Photo: Shutterstock
Press Trust of India Bhubaneswar
2 min read Last Updated : Sep 01 2020 | 8:29 PM IST

As the global quest continues for an effective panacea to forestall the spread of the CoVID-19 pandemic, GovTech pioneer CSM Technologies has designed and developed "CoVaTrack"- the first India focused Covid-19 vaccine & treatment tracker.

Under its Corporate Social Responsibility programme, CSM has tried to bring some respite to the most concerned subject of today. CoVID-19 vaccine is one of the most searched topic in the Internet as people are sifting through volumes of information to find out about the latest developments in this space. CoVaTrack is a one stop destination to get information about the vaccine development, as pharma companies, researchers and nations from across the world are working at a feverish pace to stop coronavirus in its track, which has caused enormous havoc and distress world over.

In the long-drawn process of vaccine development, CoVaTrack will keep a close track of the vaccine development efforts through multiple stages of clinical trials before regulatory approval and commercial release to market. Phase wise clinical trials are used to gauge the efficacy, dosage and side effects of either a vaccine that closely emulates the behaviour of the virus to generate antibodies or an existing drug repurposed for treating coronavirus, and similar other treatments. The tracker aims to provide every such information about the developers and researchers of ongoing trials that can encourage others in the similar lines and the development authorities to partner, invest and fast track such efforts.

The tracker aggregates publicly available information from global clinical trials registries & other credible sources. Rich visualizations in a mobile first User Interface make the tracker interactive and user friendly. This tracker of Vaccines & Treatments also looks forward to provide insights in the area of researches and novel methodologies used or invented to further the process. It will inform about the promising efforts being made to find a lasting cure and instil hope & confidence in a safer tomorrow.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Sep 01 2020 | 8:21 PM IST

Next Story